Company
Histosonics
HistoSonics has developed a non-invasive, sonic beam therapy platform that uses histotripsy, which is capable of destroying targeted liver tumors at a sub-cellular level.
Also known as HistoSonics, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Customers
- physicians and their patients
- Legal name
- HistoSonics, Inc.
- histosonics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Our mission and passion are to advance the novel science of histotripsy and its powerful benefits, bringing meaningful and transformational change to physicians and their patients.
Funding snapshot
- Total raised
- $308MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed2026-06-22
Funding rounds
- Round, 2026
- 2026-06-22
- Round, 2024
- $102M2024-07-31, SEC form D sold, 39 investors
- Round, 2022
- $85M2022-12-12, SEC form D sold, 38 investors
- Round, 2020
- $40.8M2020-04-15, SEC form D sold, 24 investors
- Round, 2019
- $47.4M2019-04-05, SEC form D sold, 44 investors
- Round, 2018
- $7M2018-04-18, SEC form D sold, 34 investors
- Round, 2017
- $8.3M2017-01-30, SEC form D sold, 13 investors
- Round, 2015
- $2.1M2015-07-29, SEC form D sold, 10 investors
- Round, 2014
- $1.5M2014-12-19, SEC form D sold, 8 investors
- Round, 2009
- $14.2M2009-12-16, SEC form D sold, 13 investors
About the company
- Status notes
- Acquired by Bezos Expeditions, Wellington K5 Global 2025
Products
- Hardware
- Edison Histotripsy System
- Web
- Edison® Histotripsy System
Exit
- Acquisition
- 2025
Loading relationship preview